infohep
  • Menu
  • Search
  • Home
  • News
  • About hepatitis
  • Countries
  • About us
  • Twitter
  • Facebook
  • RSS
  • Home
  • News
  • All the news

All the news

Showing 10 of 217 articles from: Pharmaceutical industry

Get an RSS feed of these articles

  • All news
  • infohep news
  • Editors' picks from other sources
  • HCV drug out of the running

    MedPage Today / 23 June 2014

  • UNITED STATES: FDA Approves AbbVie's Hepatitis C Regimen for Priority Review

    CDC / 19 June 2014

  • FDA lifts hold on Achillion's hepatitis C drug, shares jump

    Reuters / 11 June 2014

  • Merck to acquire hepatitis C drug developer

    Press Herald / 11 June 2014

  • French Transparency agency backs Gilead’s new hepatitis C drug Sovaldi

    EATG / The Pharma Letter / 10 June 2014

  • Top payer group shoots down Gilead's hep C drug Sovaldi on price

    FiercePharma / 22 May 2014

  • OLYSIO™ (simeprevir) receives marketing authorisation in the European Union for the treatment of adults with hepatitis C genotype 1 and 4 infection

    Reuters / 16 May 2014

  • For Drugs That Save Lives, a Steep Cost

    New York Times / 28 April 2014

  • Biotech’s Hard Bargain

    The New Yorker / 24 April 2014

  • AbbVie Submits New Drug Application to U.S. FDA for its Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Hepatitis C

    AbbVie press release / 23 April 2014

← Prev1...1617181920...22Next →
Other pages in this section
  • Latest news
  • All the news
    • Hepatitis A
    • Hepatitis B
    • Hepatitis C
    • Hepatitis D
    • Hepatitis E
    • Coronavirus
    • NAFLD
    • Treatment for hepatocellular carcinoma
    • Transmission, epidemiology and prevention
    • Health services, policy and advocacy
      • Access to medicines & diagnostics
      • Hepatitis C elimination
      • Models of care
      • Finance, funding & health economics
      • National policy
      • European policy
      • International policy
      • Activism and civil society
      • Pharmaceutical industry
    • Social issues
  • Conference news
  • Noticeboard
  • Email bulletins
  • News feeds

  • Contact us
  • Terms and conditions
  • Accessibility
  • Privacy and cookies

Latest hepatitis news

Sign-up for our monthly email bulletin Follow us on Twitter Find us on Facebook

The information on this website is intended to support, rather than replace, consultation with a healthcare professional.

©NAM Publications 2022. All rights reserved. We are not responsible for the content of external websites.

Company limited by guarantee. Registered in England & Wales, number: 2707596. Registered charity, number: 1011220

Infohep has been supported by a grant from Gilead Sciences Europe Ltd. Our funder has had no editorial control over the site’s content.

infohep

Latest treatment news and information for patient advocates and people working in hepatitis in Europe.

infohep is produced by NAM. Find out more about NAM

www.infohep.org/page//about-us/Find-out-about-NAM/page/2626330//